We are proud to catalyze research in the beautiful state of Colorado. Below is a (far from comprehensive) list of recent publications supported by the Functional Genomics Facility through reagents and expertise. Please cite the Functional Genomics Facility when appropriate, and let us know about your latest publications by emailing us at email@example.com. We'll be happy to advertise here your publications supported by the Facility.
Thank you all for your continued support!
A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. - D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK.
Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. - Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE.
Hypoxia induces triglycerides accumulation in prostate cancer cells and extracellular vesicles supporting growth and invasiveness following reoxygenation. - Schlaepfer IR, Nambiar DK, Ramteke A, Kumar R, Dhar D, Agarwal C, Bergman B, Graner M, Maroni P, Singh RP, Agarwal R, Deep G.
An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. - Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE.
C-terminal tensin-like protein mediates invasion of human lung cancer cells and is regulated by signal transducer and activator of transcription 3. - Bennett DT, Reece TB, Foley LS, Sjoberg A, Meng X, Fullerton DA, Weyant MJ.
HER2 activation results in β-catenin dependent changes in pulmonary epithelial permeability. - Finigan JH, Vasu VT, Thaikoottathil JV, Mishra R, Shatat MA, Mason RJ, Kern JA.
Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts. - Schlaepfer IR, Glodé LM, Hitz CA, Pac CT, Boyle KE, Maroni P, Deep G, Agarwal R, Lucia SM, Cramer SD, Serkova NJ, Eckel RH.
ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels. - Sullivan KD, Palaniappan VV, Espinosa JM.
Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. - Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM, Eckel RH, Cramer SD.
Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. – Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA.
Intercellular adhesion molecule-1 mediates murine colon adenocarcinoma invasion. - Howard K, Lo KK, Ao L, Gamboni F, Edil BH, Schulick R, Barnett CC Jr.
STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. - Pawlus MR, Wang L, Hu CJ.
Autophagy controls the kinetics and extent of mitochondrial apoptosis by regulating PUMA levels. - Thorburn J, Andrysik Z, Staskiewicz L, Gump J, Maycotte P, Oberst A, Green DR, Espinosa JM, Thorburn A.
STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. - Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A.
Autophagy variation within a cell population determines cell fate through selective degradation of Fap-1. -Gump JM, Staskiewicz L, Morgan MJ, Bamberg A, Riches DW, Thorburn A.
Inhibition of Wee1 sensitizes cancer cells to anti-metabolite chemotherapeutics independent of p53 functionality - Van Linden AA, Baturin D, Gardner L, Fosmire SP, Korch C, Reigan P, Porter CC.
Rapid and widespread suppression of self-renewal by microRNA-203 during epidermal differentiation - Jackson SJ, Zhang Z, Feng D, Flagg M, O'Loughlin E, Wang D, Stokes N, Fuchs E, Yi R.
A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation - Andrysik Z, Kim J, Tan AC (DT), Espinosa JM .
HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia - Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD, Espinosa JM.
Pal M, Koul S, Koul HK.
Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells - Whiteway SL, Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Foreman NK, Vibhakar R. J.
Claudins play a role in normal and tumor cell motility - Webb, P.G., Spillman, M.A., and Baumgartner, H.K.
A receptor tyrosine kinase network comprised of FGFRs, EGFR, ERBB2 and MET drives growth and survival of head and neck squamous carcinoma cell lines - Singleton KR, Kim J, Hinz TK, Marek LA, Casas-Selves M, Hatheway C, Tan AC, Degregori J, Heasley LE.
Human papillomavirus infection is inhibited by host autophagy in primary human keratinocytes - Griffin LM, Cicchini L, Pyeon D.
A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX - Henry RE, Andrysik Z, Paris R, Galbraith MD, Espinosa JM.
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53 - Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM.
ΔNp63α represses anti-proliferative genes via H2A.Z deposition - Gallant-Behm CL, Ramsey MR, Bensard CL, Nojek I, Tran J, Liu M, Ellisen LW, Espinosa JM.
Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia - Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, DeGregori J.
mRNA decapping factors and the exonuclease Xrn2 function in widespread premature termination of RNA polymerase II transcription - Brannan K, Kim H, Erickson B, Glover-Cutter K, Kim S, Fong N, Kiemele L, Hansen K, Davis R, Lykke-Andersen J, Bentley DL.
Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer - Cochrane DR, Jacobsen BM, Connaghan KD, Howe EN, Bain DL, Richer JK.
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition - Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC, DeGregori J.
West Nile virus growth is independent of autophagy activation - Beatman E, Oyer R, Shives KD, Hedman K, Brault AC, Tyler KL, Beckham JD.
Trisomy 21 consistently activates the interferon response. - Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, Smith KP, Liggett LA, Gomez EB, Galbraith MD, DeGregori J, Espinosa JM.
GON4L drives cancer growth through a YY1- androgen receptor-CD24 axis. - Agarwal N, Dancik GM, Goodspeed A, Costello JC, Owens C, Duex JE, Theodorescu D.
Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. - Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG.
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. - Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR.